Welcome to our dedicated page for AtriCure SEC filings (Ticker: ATRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AtriCure's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AtriCure's regulatory disclosures and financial reporting.
AtriCure, Inc. (ATRC) reported that Chief Technical Officer Salvatore Privitera sold 7,763 shares of common stock on September 2, 2026 at a price of $52.50 per share in an open-market or private transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2026. After this transaction, he held 150,921 shares of AtriCure common stock directly.
AtriCure, Inc. (ATRC) received a notice that officer Salvatore Privitera intends to sell 7,763 shares of common stock under Rule 144. The shares were acquired from the issuer as restricted stock that vested during the period from March 1, 2020 through March 1, 2021. The proposed sale, through Morgan Stanley Smith Barney’s Executive Financial Services unit, reflects an estimated aggregate market value of $407,557.50 and is associated with trading on NASDAQ.
AtriCure, Inc. (ATRC) reported that Chief Legal Officer Karl S. Dahlquist sold 9,370 shares of common stock on 2026-08-24 in a sale classified as an open market or private transaction. The weighted average sales price was approximately $48.89 per share, with trades executed between $48.88 and $48.89. Following this transaction, Dahlquist directly holds 87,319 AtriCure common shares.
AtriCure, Inc. (ATRC) received a Rule 144 notice from officer Karl Scott Dahlquist covering potential sales of its common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on Nasdaq. The notice lists 9,370 common shares tied to performance shares, restricted stock, and Employee Stock Purchase Plan acquisitions.
AllianceBernstein L.P. filed an amended Schedule 13G reporting beneficial ownership of AtriCure Inc common stock. As of June 30, 2026, AllianceBernstein reported beneficial ownership of 2,768,365 shares, representing 5.5% of AtriCure’s outstanding common stock. The shares are held solely for investment purposes in client discretionary investment advisory accounts.
AllianceBernstein reported sole voting power over 2,631,027 shares and sole dispositive power over 2,737,665 shares, with an additional 30,700 shares subject to shared dispositive power and no shared voting power. AllianceBernstein is a Delaware partnership and a majority-owned subsidiary of Equitable Holdings, Inc., but states it operates under independent management and makes independent decisions from its parent.
AtriCure, Inc. director Karen Prange reported a sale of 3,564 shares of Common Stock on 2026-08-05 at $38.80 per share in a sale in open market or private transaction. Following this transaction, she directly holds 22,809 AtriCure shares.
AtriCure, Inc. director Maggie Yuen reported selling 3,500 shares of Common Stock on August 5, 2026. The shares were sold in multiple trades at prices between $38.37 and $38.43, for a weighted average price of $38.42 per share. Following this transaction, she holds 14,015 shares directly. The Rule 10b5-1 trading plan checkbox was not selected.
AtriCure, Inc. insider Karen Prange filed a notice of intent to sell 3,564 shares of common stock held through Fidelity Brokerage Services LLC on NASDAQ. These shares relate to a stock award dated May 26, 2023. AtriCure had 50,866,294 shares of common stock outstanding in connection with this notice. Over the prior three months, Prange sold 1,000 shares of common stock for $28,759.40 on May 20, 2026 and 2,000 shares for $57,188.82 on May 21, 2026.
Michael H. Carrel, President, CEO, & Director of AtriCure, Inc., reported bona fide gifts of 4,700 shares of common stock on July 30, 2026. These included 700 shares to a parent and 4,000 shares as a charitable gift, with no consideration received. He also reports indirect holdings of 14,310 shares held by his children, 2,950 shares held by a parent, and 1,000 shares held by a sibling, for which he disclaims beneficial ownership except for his pecuniary interest.